Cargando…

A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First‐line Therapy (KCSG ST10‐01)

LESSONS LEARNED. Irinotecan could not be proven noninferior to paclitaxel as a second‐line treatment for patients with metastatic or recurrent gastric cancer. The failure to demonstrate noninferiority may have been a result of insufficient patient enrollment. Both agents were tolerable but showed di...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Keun‐Wook, Maeng, Chi Hoon, Kim, Tae‐You, Zang, Dae Young, Kim, Yeul Hong, Hwang, In Gyu, Oh, Sang Cheul, Chung, Joo Seop, Song, Hong Suk, Kim, Jin Won, Jeong, Su Jin, Cho, Jae Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324622/
https://www.ncbi.nlm.nih.gov/pubmed/30126861
http://dx.doi.org/10.1634/theoncologist.2018-0142
_version_ 1783386006670540800
author Lee, Keun‐Wook
Maeng, Chi Hoon
Kim, Tae‐You
Zang, Dae Young
Kim, Yeul Hong
Hwang, In Gyu
Oh, Sang Cheul
Chung, Joo Seop
Song, Hong Suk
Kim, Jin Won
Jeong, Su Jin
Cho, Jae Yong
author_facet Lee, Keun‐Wook
Maeng, Chi Hoon
Kim, Tae‐You
Zang, Dae Young
Kim, Yeul Hong
Hwang, In Gyu
Oh, Sang Cheul
Chung, Joo Seop
Song, Hong Suk
Kim, Jin Won
Jeong, Su Jin
Cho, Jae Yong
author_sort Lee, Keun‐Wook
collection PubMed
description LESSONS LEARNED. Irinotecan could not be proven noninferior to paclitaxel as a second‐line treatment for patients with metastatic or recurrent gastric cancer. The failure to demonstrate noninferiority may have been a result of insufficient patient enrollment. Both agents were tolerable but showed different toxicity profiles. BACKGROUND. This phase III study compared the efficacy and safety of paclitaxel versus irinotecan in patients with metastatic or recurrent gastric cancer (MRGC) who had experienced disease progression following first‐line chemotherapy. METHODS. Patients were randomized to receive either paclitaxel (70 mg/m(2); days 1, 8, 15, every 4 weeks) or irinotecan (150 mg/m(2) every other week). The primary endpoint was progression‐free survival (PFS). RESULTS. This study was stopped early due to low accrual rate. A total of 112 patients were enrolled; 54 were allocated to paclitaxel and 58 to irinotecan. Median PFS for the paclitaxel and irinotecan groups was 3.5 and 2.1 months, respectively (hazard ratio [HR], 1.27; 95% confidence interval [CI], 0.86–1.88; p = .234). Noninferiority of irinotecan to paclitaxel was not proved because the upper boundary of the 95% CI (1.88) exceeded the predefined upper margin of noninferiority (1.32). Median overall survival (OS) was 8.6 months in the paclitaxel group and 7.0 months in the irinotecan group (HR, 1.39; 95% CI, 0.91–2.11; p = .126). Among toxicities greater than or equal to grade 3, neutropenia (11.5%) was the most common, followed by peripheral neuropathy (7.7%) in the paclitaxel group, and neutropenia (34.5%) followed by nausea, vomiting, and anemia (8.6%, respectively) in the irinotecan group. CONCLUSION. Although paclitaxel showed numerically longer PFS and OS compared with irinotecan, this was statistically insignificant. Both irinotecan and paclitaxel are valid second‐line treatment options in MRGC.
format Online
Article
Text
id pubmed-6324622
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-63246222019-01-18 A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First‐line Therapy (KCSG ST10‐01) Lee, Keun‐Wook Maeng, Chi Hoon Kim, Tae‐You Zang, Dae Young Kim, Yeul Hong Hwang, In Gyu Oh, Sang Cheul Chung, Joo Seop Song, Hong Suk Kim, Jin Won Jeong, Su Jin Cho, Jae Yong Oncologist Clinical Trial Results LESSONS LEARNED. Irinotecan could not be proven noninferior to paclitaxel as a second‐line treatment for patients with metastatic or recurrent gastric cancer. The failure to demonstrate noninferiority may have been a result of insufficient patient enrollment. Both agents were tolerable but showed different toxicity profiles. BACKGROUND. This phase III study compared the efficacy and safety of paclitaxel versus irinotecan in patients with metastatic or recurrent gastric cancer (MRGC) who had experienced disease progression following first‐line chemotherapy. METHODS. Patients were randomized to receive either paclitaxel (70 mg/m(2); days 1, 8, 15, every 4 weeks) or irinotecan (150 mg/m(2) every other week). The primary endpoint was progression‐free survival (PFS). RESULTS. This study was stopped early due to low accrual rate. A total of 112 patients were enrolled; 54 were allocated to paclitaxel and 58 to irinotecan. Median PFS for the paclitaxel and irinotecan groups was 3.5 and 2.1 months, respectively (hazard ratio [HR], 1.27; 95% confidence interval [CI], 0.86–1.88; p = .234). Noninferiority of irinotecan to paclitaxel was not proved because the upper boundary of the 95% CI (1.88) exceeded the predefined upper margin of noninferiority (1.32). Median overall survival (OS) was 8.6 months in the paclitaxel group and 7.0 months in the irinotecan group (HR, 1.39; 95% CI, 0.91–2.11; p = .126). Among toxicities greater than or equal to grade 3, neutropenia (11.5%) was the most common, followed by peripheral neuropathy (7.7%) in the paclitaxel group, and neutropenia (34.5%) followed by nausea, vomiting, and anemia (8.6%, respectively) in the irinotecan group. CONCLUSION. Although paclitaxel showed numerically longer PFS and OS compared with irinotecan, this was statistically insignificant. Both irinotecan and paclitaxel are valid second‐line treatment options in MRGC. John Wiley & Sons, Inc. 2018-08-20 2019-01 /pmc/articles/PMC6324622/ /pubmed/30126861 http://dx.doi.org/10.1634/theoncologist.2018-0142 Text en © AlphaMed Press; the data published online to support this summary is the property of the authors
spellingShingle Clinical Trial Results
Lee, Keun‐Wook
Maeng, Chi Hoon
Kim, Tae‐You
Zang, Dae Young
Kim, Yeul Hong
Hwang, In Gyu
Oh, Sang Cheul
Chung, Joo Seop
Song, Hong Suk
Kim, Jin Won
Jeong, Su Jin
Cho, Jae Yong
A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First‐line Therapy (KCSG ST10‐01)
title A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First‐line Therapy (KCSG ST10‐01)
title_full A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First‐line Therapy (KCSG ST10‐01)
title_fullStr A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First‐line Therapy (KCSG ST10‐01)
title_full_unstemmed A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First‐line Therapy (KCSG ST10‐01)
title_short A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First‐line Therapy (KCSG ST10‐01)
title_sort phase iii study to compare the efficacy and safety of paclitaxel versus irinotecan in patients with metastatic or recurrent gastric cancer who failed in first‐line therapy (kcsg st10‐01)
topic Clinical Trial Results
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324622/
https://www.ncbi.nlm.nih.gov/pubmed/30126861
http://dx.doi.org/10.1634/theoncologist.2018-0142
work_keys_str_mv AT leekeunwook aphaseiiistudytocomparetheefficacyandsafetyofpaclitaxelversusirinotecaninpatientswithmetastaticorrecurrentgastriccancerwhofailedinfirstlinetherapykcsgst1001
AT maengchihoon aphaseiiistudytocomparetheefficacyandsafetyofpaclitaxelversusirinotecaninpatientswithmetastaticorrecurrentgastriccancerwhofailedinfirstlinetherapykcsgst1001
AT kimtaeyou aphaseiiistudytocomparetheefficacyandsafetyofpaclitaxelversusirinotecaninpatientswithmetastaticorrecurrentgastriccancerwhofailedinfirstlinetherapykcsgst1001
AT zangdaeyoung aphaseiiistudytocomparetheefficacyandsafetyofpaclitaxelversusirinotecaninpatientswithmetastaticorrecurrentgastriccancerwhofailedinfirstlinetherapykcsgst1001
AT kimyeulhong aphaseiiistudytocomparetheefficacyandsafetyofpaclitaxelversusirinotecaninpatientswithmetastaticorrecurrentgastriccancerwhofailedinfirstlinetherapykcsgst1001
AT hwangingyu aphaseiiistudytocomparetheefficacyandsafetyofpaclitaxelversusirinotecaninpatientswithmetastaticorrecurrentgastriccancerwhofailedinfirstlinetherapykcsgst1001
AT ohsangcheul aphaseiiistudytocomparetheefficacyandsafetyofpaclitaxelversusirinotecaninpatientswithmetastaticorrecurrentgastriccancerwhofailedinfirstlinetherapykcsgst1001
AT chungjooseop aphaseiiistudytocomparetheefficacyandsafetyofpaclitaxelversusirinotecaninpatientswithmetastaticorrecurrentgastriccancerwhofailedinfirstlinetherapykcsgst1001
AT songhongsuk aphaseiiistudytocomparetheefficacyandsafetyofpaclitaxelversusirinotecaninpatientswithmetastaticorrecurrentgastriccancerwhofailedinfirstlinetherapykcsgst1001
AT kimjinwon aphaseiiistudytocomparetheefficacyandsafetyofpaclitaxelversusirinotecaninpatientswithmetastaticorrecurrentgastriccancerwhofailedinfirstlinetherapykcsgst1001
AT jeongsujin aphaseiiistudytocomparetheefficacyandsafetyofpaclitaxelversusirinotecaninpatientswithmetastaticorrecurrentgastriccancerwhofailedinfirstlinetherapykcsgst1001
AT chojaeyong aphaseiiistudytocomparetheefficacyandsafetyofpaclitaxelversusirinotecaninpatientswithmetastaticorrecurrentgastriccancerwhofailedinfirstlinetherapykcsgst1001
AT leekeunwook phaseiiistudytocomparetheefficacyandsafetyofpaclitaxelversusirinotecaninpatientswithmetastaticorrecurrentgastriccancerwhofailedinfirstlinetherapykcsgst1001
AT maengchihoon phaseiiistudytocomparetheefficacyandsafetyofpaclitaxelversusirinotecaninpatientswithmetastaticorrecurrentgastriccancerwhofailedinfirstlinetherapykcsgst1001
AT kimtaeyou phaseiiistudytocomparetheefficacyandsafetyofpaclitaxelversusirinotecaninpatientswithmetastaticorrecurrentgastriccancerwhofailedinfirstlinetherapykcsgst1001
AT zangdaeyoung phaseiiistudytocomparetheefficacyandsafetyofpaclitaxelversusirinotecaninpatientswithmetastaticorrecurrentgastriccancerwhofailedinfirstlinetherapykcsgst1001
AT kimyeulhong phaseiiistudytocomparetheefficacyandsafetyofpaclitaxelversusirinotecaninpatientswithmetastaticorrecurrentgastriccancerwhofailedinfirstlinetherapykcsgst1001
AT hwangingyu phaseiiistudytocomparetheefficacyandsafetyofpaclitaxelversusirinotecaninpatientswithmetastaticorrecurrentgastriccancerwhofailedinfirstlinetherapykcsgst1001
AT ohsangcheul phaseiiistudytocomparetheefficacyandsafetyofpaclitaxelversusirinotecaninpatientswithmetastaticorrecurrentgastriccancerwhofailedinfirstlinetherapykcsgst1001
AT chungjooseop phaseiiistudytocomparetheefficacyandsafetyofpaclitaxelversusirinotecaninpatientswithmetastaticorrecurrentgastriccancerwhofailedinfirstlinetherapykcsgst1001
AT songhongsuk phaseiiistudytocomparetheefficacyandsafetyofpaclitaxelversusirinotecaninpatientswithmetastaticorrecurrentgastriccancerwhofailedinfirstlinetherapykcsgst1001
AT kimjinwon phaseiiistudytocomparetheefficacyandsafetyofpaclitaxelversusirinotecaninpatientswithmetastaticorrecurrentgastriccancerwhofailedinfirstlinetherapykcsgst1001
AT jeongsujin phaseiiistudytocomparetheefficacyandsafetyofpaclitaxelversusirinotecaninpatientswithmetastaticorrecurrentgastriccancerwhofailedinfirstlinetherapykcsgst1001
AT chojaeyong phaseiiistudytocomparetheefficacyandsafetyofpaclitaxelversusirinotecaninpatientswithmetastaticorrecurrentgastriccancerwhofailedinfirstlinetherapykcsgst1001